Novo NVO shares have fallen 11.1% over the past month, with the Capital Markets Day in London on Sept. 21 emerging as the ...

There's mounting evidence that GLP-1 drugs might curb one's desire to gamble by altering the brain's reward system.

One platform, Suno, outputs the equivalent of Spotify’s entire catalogue once a fortnight, but it’s impossible to know who’s ...

Ellen Relkin, attorney and co-lead counsel in the New Jersey Ozempic lawsuits on NAION vision loss, shares exclusive insight and guidelines for anyone taking a GLP-1 medication.

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

Consolidation of Instrument Cluster and Infotainment System Helps Deliver a Unified In-Vehicle Experience and Optimized ...

Spread the love“`html Imagine a world where obesity, a complex and often debilitating disease, could be effectively managed ...

Spread the loveIf you’re an adult living with obesity, you know the struggle is real. It’s not just about willpower or diet ...

Big Pharma scoffed. But Daniel Drucker’s dogged pursuit of a secret buried in lizard genes propelled a mega medical ...

A pair of studies have found evidence that GLP-1 users are more likely to lose thei. Reading time 4 minutes GLP-1 medications like semaglutide and tirzepatide may come with some unexpected ...

Childhood obesity treatment India may see new pilots as Novo Nordisk seeks wider public funding for GLP-1 medicines and ...